Impact of nonpharmaceutical interventions on inflammatory diseases of the nose

非药物干预对鼻部炎症性疾病的影响

阅读:2

Abstract

AIM: This study aimed to investigate the impact of nonpharmaceutical interventions (NPIs), implemented by the Chinese government during 2020-2022 to reduce the spread of coronavirus disease 2019, on the incidence of inflammatory nasal diseases, including chronic nonallergic rhinitis, allergic rhinitis, acute rhinitis, chronic sinusitis and acute sinusitis. METHODS: Medical records from the Department of Otorhinolaryngology of the Hangzhou Normal University Affiliated Hospital were analysed to compare the incidence of the five nasal diseases between the pre-pandemic (January 2018-December 2019) and the pandemic prevention periods (January 2020-December 2022). The Chi-square test was used to compare incidence rates and sex/age distributions. RESULTS: The incidence of chronic nonallergic rhinitis, chronic sinusitis and acute sinusitis decreased significantly during the pandemic prevention period (p < .001), while the incidence of allergic rhinitis and acute rhinitis increased significantly (p < .001). NPIs were protective factors for chronic nonallergic rhinitis, chronic rhinosinusitis and acute rhinosinusitis (relative risk (RR) < 1) but risk factors for allergic rhinitis and acute rhinitis (RR > 1). The proportion of male patients increased significantly for chronic nonallergic rhinitis and chronic sinusitis (p < .001). The age of the patients showed significant differences in the four diseases - chronic nonallergic rhinitis, allergic rhinitis, chronic sinusitis and acute sinusitis (p < .001). CONCLUSIONS: NPIs had a significant impact on the incidence and epidemiology of nasal inflammatory diseases, with significant differences in incidence rate, sex and age distribution between the pre-pandemic and pandemic prevention periods.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。